Company news
Bioxcel Therapeutics, Inc. (NASDAQ:BTAI) news
Bioxcel Therapeutics, Inc. news releases on 6ix. Latest, Nov 8, 2024: BioXcel Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024
Press releases — page 2
BioXcel Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024
November 7, 2024
BioXcel Therapeutics to Present at ThinkEquity Conference
October 28, 2024
BioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of BXCL501 (Sublingual Dexmedetomidine) for Treating Acute Stress Disorder
October 14, 2024
BioXcel Therapeutics Announces Clinical Prioritization and Update on BXCL501 Late-Stage Programs for Agitation
September 18, 2024
BioXcel Therapeutics Announces Initiation of SERENITY At-Home Pivotal Phase 3 Safety Trial of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
September 4, 2024
BioXcel Therapeutics to Participate in Canaccord Genuity 44th Annual Growth Conference
August 6, 2024
BioXcel Therapeutics Reports Second Quarter 2024 Financial Results
August 5, 2024
BioXcel Therapeutics to Report Second Quarter 2024 Financial Results on August 6, 2024
July 29, 2024
BioXcel Therapeutics Announces Preliminary Estimated Unaudited Second Quarter Net Revenues from Sales of IGALMI™ (dexmedetomidine) Sublingual Film
July 15, 2024
BioXcel Therapeutics Announces Positive Topline Results from Post-Marketing Requirement Study Evaluating PRN Treatment of IGALMI™ (dexmedetomidine) Sublingual Film for Agitation Associated with Bipolar Disorders or Schizophrenia
June 24, 2024
BioXcel Therapeutics to Present at Jefferies Global Healthcare Conference
May 27, 2024
BioXcel Therapeutics Announces Oral and Poster Presentations at the 2024 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
May 20, 2024
BioXcel Therapeutics Reports First Quarter 2024 Financial Results
May 8, 2024
BioXcel Therapeutics to Report First Quarter 2024 Financial Results on May 9, 2024
April 24, 2024
BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting
April 23, 2024
BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential
April 21, 2024
BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer’s Dementia
April 9, 2024
BioXcel Therapeutics Announces $25 Million Registered Direct Offering
March 24, 2024
BioXcel Therapeutics Announces European Patent Office’s Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual Dexmedetomidine
March 14, 2024
BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2023
March 11, 2024
BioXcel Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024
February 29, 2024
BioXcel Therapeutics Announces Termination of Proposed Public Offering
February 12, 2024
BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL701 for Treatment of Small Cell Neuroendocrine Prostate Cancer (SCNC)
February 11, 2024
BioXcel Therapeutics Announces Completion of Patient Enrollment in Safety Portion of Investigator-Sponsored Phase 2 Relapsed Pancreatic Cancer Trial of BXCL701 in Combination with KEYTRUDA®
February 5, 2024
BioXcel Therapeutics Announces USPTO’s Allowance of Patent Application for Method of Treating Agitation in Alzheimer’s Disease Using Oromucosal Formulations of Dexmedetomidine
February 4, 2024
BioXcel Therapeutics Hosting Virtual Neuroscience R&D Day Today
December 11, 2023
BioXcel Therapeutics Strengthens Clinical Development Leadership to Advance Late-Stage Programs
December 10, 2023
BioXcel Therapeutics to Host Virtual Neuroscience R&D Day on Dec. 12, 2023
November 29, 2023
BioXcel Therapeutics Aligns with FDA Recommendation for Phase 3 Trial for TRANQUILITY Program, Provides Update on Strategic Financing, and Reports Third Quarter 2023 Financial Results
November 13, 2023
BioXcel Therapeutics Reports Positive Overall Survival Results from Single-Arm, Open-Label Phase 2 Trial of BXCL701 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) of Adenocarcinoma Phenotype
November 7, 2023
BioXcel Therapeutics Announces Update on NIDA-funded Trial of BXCL501 (sublingual dexmedetomidine) for Potential Treatment of Opioid Use Disorder (OUD)
November 5, 2023
BioXcel Therapeutics to Report Third Quarter 2023 Financial Results on November 14, 2023
October 30, 2023
BioXcel Therapeutics Receives Permanent J-Code for IGALMI™ (dexmedetomidine) Sublingual Film from Centers for Medicare & Medicaid Services
October 29, 2023
BioXcel Therapeutics Announces Positive Findings from Independent Third Party Audit of Data Integrity at TRANQUILITY II Phase 3 Trial Site
October 24, 2023
BioXcel Therapeutics Reports Positive Overall Survival Results from Single-Arm, Open-Label Phase 2 Trial of BXCL701 in Patients with Small Cell Neuroendocrine Prostate Cancer
October 9, 2023
BioXcel Therapeutics Provides Update on Recent Developments for Late-Stage Clinical Programs and Expansion of IP Portfolio for IGALMI™ (dexmedetomidine) Sublingual Film
October 3, 2023
BioXcel Therapeutics Reports Second Quarter 2023 Financial Results and Announces Strategic Reprioritization
August 13, 2023
BioXcel Therapeutics to Report Second Quarter 2023 Financial Results on August 14, 2023
July 30, 2023
BioXcel Therapeutics Announces Positive Topline Results From TRANQUILITY II Phase 3 Trial of BXCL501 for Acute Treatment of Alzheimer’s Disease-Related Agitation
June 28, 2023
BioXcel Therapeutics to Participate at Two Upcoming Investor Conferences
May 31, 2023
BioXcel Therapeutics Announces Promising Topline Results from Part 1 of Pivotal SERENITY III Trial of BXCL501 for At-Home Use in Acute Treatment of Agitation in Bipolar Disorders or Schizophrenia
May 24, 2023
BioXcel Therapeutics Announces Positive Top-Line Data from Repeat Dosing of BXCL501 in Phase 1b Multiple Ascending Dose Trial in Healthy Volunteers for Major Depressive Disorder (MDD) Program
May 15, 2023
BioXcel Therapeutics Reports First Quarter 2023 Financial Results and Recent Operational Highlights
May 7, 2023
BioXcel Therapeutics to Present at the BofA Securities 2023 Health Care Conference
May 1, 2023
BioXcel Therapeutics to Report First Quarter 2023 Financial Results on May 8, 2023
April 23, 2023
OnkosXcel Therapeutics Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering
March 13, 2023
BioXcel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Highlights
March 8, 2023
BioXcel Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 9, 2023
February 22, 2023
BioXcel Therapeutics to Ring Nasdaq Stock Market Closing Bell Today
February 20, 2023
BioXcel Therapeutics Announces Positive Full Data from Phase 2 Trial of BXCL701 in Rare, Aggressive Form of Prostate Cancer; to be Presented at 2023 ASCO Genitourinary Cancers Symposium
February 12, 2023